Skip to main content
Top
Published in: Breast Cancer Research 2/2011

Open Access 01-04-2011 | Research article

The indole-3-carbinol cyclic tetrameric derivative CTet inhibits cell proliferation via overexpression of p21/CDKN1A in both estrogen receptor-positive and triple-negative breast cancer cell lines

Authors: Mauro De Santi, Luca Galluzzi, Simone Lucarini, Maria Filomena Paoletti, Alessandra Fraternale, Andrea Duranti, Cinzia De Marco, Mirco Fanelli, Nadia Zaffaroni, Giorgio Brandi, Mauro Magnani

Published in: Breast Cancer Research | Issue 2/2011

Login to get access

Abstract

Introduction

Indole-3-carbinol (I3C), an autolysis product of glucosinolates present in cruciferous vegetables, and its dimeric derivative (3,3'-DIM) have been indicated as promising agents in preventing the development and progression of breast cancer. We have recently shown that I3C cyclic tetrameric derivative CTet formulated in γ-cyclodextrin (γ-CD) efficiently inhibited cellular proliferation in breast cancer cell lines. This study aims to analyze the mechanisms involved in the in vitro inhibition of cell proliferation and to evaluate the in vivo antitumor activity of CTet in a xenograft study.

Methods

Estrogen receptor-positive MCF-7 and triple-negative MDA-MB-231 breast cancer cell lines were exposed to CTet to evaluate cell cycle perturbation (propidium iodide staining and cytofluorimetric acquisition), induction of autophagic morphological features (co-localization of LC3b autophagosome marker and LAMP2a lysosome marker by immunofluorescence) and changes in protein expression (immunoblot and microarray-based gene expression analyses). To test the in vivo efficacy of CTet, female athymic nude mice inoculated with MCF-7 cells were i.p. treated with 5 mg/kg/day of CTet for five days/week for two weeks and the tumor mass was externally monitored.

Results

CTet induced accumulation in G2/M phase without evidence of apoptotic response induction in both cell lines tested. In triple-negative MDA-MB-231 the autophagic lysosomal activity was significantly up-regulated after exposure to 4 μM of CTet for 8 hours, while the highest CTet concentration was necessary to observe autophagic features in MCF-7 cells. The inhibition of Akt activity and p53-independent p21/CDKN1A and GADD45A overexpression were identified as the main molecular events responsible for CTet activity in MCF-7 and p53-mutant MDA-MB-231 cells. In vivo, CTet administration was able to significantly inhibit the growth of MCF-7 xenotransplanted into nude mice, without adverse effect on body weight or on haematological parameters.

Conclusions

Our data support CTet formulated with γ-CD as a promising and injectable anticancer agent for both hormone-responsive and triple-negative breast tumors.
Appendix
Available only for authorised users
Literature
1.
go back to reference Chacón RD, Costanzo MV: Triple-negative breast cancer. Breast Cancer Res. 2010, 12 Suppl 2: S3-PubMed Chacón RD, Costanzo MV: Triple-negative breast cancer. Breast Cancer Res. 2010, 12 Suppl 2: S3-PubMed
2.
go back to reference Cleator S, Heller W, Coombes RC: Triple-negative breast cancer: therapeutic options. Lancet Oncol. 2007, 8: 235-244. 10.1016/S1470-2045(07)70074-8.PubMed Cleator S, Heller W, Coombes RC: Triple-negative breast cancer: therapeutic options. Lancet Oncol. 2007, 8: 235-244. 10.1016/S1470-2045(07)70074-8.PubMed
3.
go back to reference Coffer PJ, Jin J, Woodgett JR: Protein kinase B (c-Akt): a multifunctional mediator of phosphatidylinositol 3-kinase activation. Biochem J. 1998, 335: 1-13.PubMedPubMedCentral Coffer PJ, Jin J, Woodgett JR: Protein kinase B (c-Akt): a multifunctional mediator of phosphatidylinositol 3-kinase activation. Biochem J. 1998, 335: 1-13.PubMedPubMedCentral
4.
go back to reference Higdon JV, Delage B, Williams DE, Dashwood RH: Cruciferous vegetables and human cancer risk: epidemiologic evidence and mechanistic basis. Pharmacol Res. 2007, 55: 224-236. 10.1016/j.phrs.2007.01.009.PubMedPubMedCentral Higdon JV, Delage B, Williams DE, Dashwood RH: Cruciferous vegetables and human cancer risk: epidemiologic evidence and mechanistic basis. Pharmacol Res. 2007, 55: 224-236. 10.1016/j.phrs.2007.01.009.PubMedPubMedCentral
5.
go back to reference Minich DM, Bland JS: A review of the clinical efficacy and safety of cruciferous vegetable phytochemicals. Nutr Rev. 2007, 65: 259-267. 10.1111/j.1753-4887.2007.tb00303.x.PubMed Minich DM, Bland JS: A review of the clinical efficacy and safety of cruciferous vegetable phytochemicals. Nutr Rev. 2007, 65: 259-267. 10.1111/j.1753-4887.2007.tb00303.x.PubMed
6.
go back to reference Verhoeven DT, Goldbohm RA, van Poppel G, Verhagen H, van den Brandt PA: Epidemiological studies on brassica vegetables and cancer risk. Cancer Epidemiol Biomarkers Prev. 1996, 5: 733-748.PubMed Verhoeven DT, Goldbohm RA, van Poppel G, Verhagen H, van den Brandt PA: Epidemiological studies on brassica vegetables and cancer risk. Cancer Epidemiol Biomarkers Prev. 1996, 5: 733-748.PubMed
7.
go back to reference Weng JR, Tsai CH, Kulp SK, Chen CS: Indole-3-carbinol as a chemopreventive and anti-cancer agent. Cancer Lett. 2008, 262: 153-163. 10.1016/j.canlet.2008.01.033.PubMedPubMedCentral Weng JR, Tsai CH, Kulp SK, Chen CS: Indole-3-carbinol as a chemopreventive and anti-cancer agent. Cancer Lett. 2008, 262: 153-163. 10.1016/j.canlet.2008.01.033.PubMedPubMedCentral
8.
go back to reference Aggarwal BB, Ichikawa H: Molecular targets and anticancer potential of indole-3-carbinol and its derivatives. Cell Cycle. 2005, 4: 1201-1215. 10.4161/cc.4.9.1993.PubMed Aggarwal BB, Ichikawa H: Molecular targets and anticancer potential of indole-3-carbinol and its derivatives. Cell Cycle. 2005, 4: 1201-1215. 10.4161/cc.4.9.1993.PubMed
9.
go back to reference Howells LM, Gallacher-Horley B, Houghton CE, Manson MM, Hudson EA: Indole-3-carbinol inhibits protein kinase B/Akt and induces apoptosis in the human breast tumor cell line MDA MB468 but not in the nontumorigenic HBL100 line. Mol Cancer Ther. 2002, 1: 1161-1172.PubMed Howells LM, Gallacher-Horley B, Houghton CE, Manson MM, Hudson EA: Indole-3-carbinol inhibits protein kinase B/Akt and induces apoptosis in the human breast tumor cell line MDA MB468 but not in the nontumorigenic HBL100 line. Mol Cancer Ther. 2002, 1: 1161-1172.PubMed
10.
go back to reference Rahman KM, Li Y, Sarkar FH: Inactivation of akt and NF-kappaB play important roles during indole-3-carbinol-induced apoptosis in breast cancer cells. Nutr Cancer. 2004, 48: 84-94. 10.1207/s15327914nc4801_12.PubMed Rahman KM, Li Y, Sarkar FH: Inactivation of akt and NF-kappaB play important roles during indole-3-carbinol-induced apoptosis in breast cancer cells. Nutr Cancer. 2004, 48: 84-94. 10.1207/s15327914nc4801_12.PubMed
11.
go back to reference Rahman KW, Sarkar FH: Inhibition of nuclear translocation of nuclear factor-{kappa}B contributes to 3,3'-diindolylmethane-induced apoptosis in breast cancer cells. Cancer Res. 2005, 65: 364-371.PubMed Rahman KW, Sarkar FH: Inhibition of nuclear translocation of nuclear factor-{kappa}B contributes to 3,3'-diindolylmethane-induced apoptosis in breast cancer cells. Cancer Res. 2005, 65: 364-371.PubMed
12.
go back to reference Grose KR, Bjeldanes LF: Oligomerization of indole-3-carbinol in aqueous acid. Chem Res Toxicol. 1992, 5: 188-193. 10.1021/tx00026a007.PubMed Grose KR, Bjeldanes LF: Oligomerization of indole-3-carbinol in aqueous acid. Chem Res Toxicol. 1992, 5: 188-193. 10.1021/tx00026a007.PubMed
13.
go back to reference Safe S, Papineni S, Chintharlapalli S: Cancer chemotherapy with indole-3-carbinol, bis(3'-indolyl)methane and synthetic analogs. Cancer Lett. 2008, 269: 326-338. 10.1016/j.canlet.2008.04.021.PubMedPubMedCentral Safe S, Papineni S, Chintharlapalli S: Cancer chemotherapy with indole-3-carbinol, bis(3'-indolyl)methane and synthetic analogs. Cancer Lett. 2008, 269: 326-338. 10.1016/j.canlet.2008.04.021.PubMedPubMedCentral
14.
go back to reference Firestone GL, Bjeldanes LF: Indole-3-carbinol and 3-3'-diindolylmethane antiproliferative signaling pathways control cell-cycle gene transcription in human breast cancer cells by regulating promoter-Sp1 transcription factor interactions. J Nutr. 2003, 133: 2448S-2455S.PubMed Firestone GL, Bjeldanes LF: Indole-3-carbinol and 3-3'-diindolylmethane antiproliferative signaling pathways control cell-cycle gene transcription in human breast cancer cells by regulating promoter-Sp1 transcription factor interactions. J Nutr. 2003, 133: 2448S-2455S.PubMed
15.
go back to reference Cover CM, Hsieh SJ, Tran SH, Hallden G, Kim GS, Bjeldanes LF, Firestone GL: Indole-3-carbinol inhibits the expression of cyclin-dependent kinase-6 and induces a G1 cell cycle arrest of human breast cancer cells independent of estrogen receptor signaling. J Biol Chem. 1998, 273: 3838-3847. 10.1074/jbc.273.7.3838.PubMed Cover CM, Hsieh SJ, Tran SH, Hallden G, Kim GS, Bjeldanes LF, Firestone GL: Indole-3-carbinol inhibits the expression of cyclin-dependent kinase-6 and induces a G1 cell cycle arrest of human breast cancer cells independent of estrogen receptor signaling. J Biol Chem. 1998, 273: 3838-3847. 10.1074/jbc.273.7.3838.PubMed
16.
go back to reference Cram EJ, Liu BD, Bjeldanes LF, Firestone GL: Indole-3-carbinol inhibits CDK6 expression in human MCF-7 breast cancer cells by disrupting Sp1 transcription factor interactions with a composite element in the CDK6 gene promoter. J Biol Chem. 2001, 276: 22332-22340. 10.1074/jbc.M010539200.PubMed Cram EJ, Liu BD, Bjeldanes LF, Firestone GL: Indole-3-carbinol inhibits CDK6 expression in human MCF-7 breast cancer cells by disrupting Sp1 transcription factor interactions with a composite element in the CDK6 gene promoter. J Biol Chem. 2001, 276: 22332-22340. 10.1074/jbc.M010539200.PubMed
17.
go back to reference Jump SM, Kung J, Staub R, Kinseth MA, Cram EJ, Yudina LN, Preobrazhenskaya MN, Bjeldanes LF, Firestone GL: N-Alkoxy derivatization of indole-3-carbinol increases the efficacy of the G1 cell cycle arrest and of I3C-specific regulation of cell cycle gene transcription and activity in human breast cancer cells. Biochem Pharmacol. 2008, 75: 713-724. 10.1016/j.bcp.2007.09.024.PubMed Jump SM, Kung J, Staub R, Kinseth MA, Cram EJ, Yudina LN, Preobrazhenskaya MN, Bjeldanes LF, Firestone GL: N-Alkoxy derivatization of indole-3-carbinol increases the efficacy of the G1 cell cycle arrest and of I3C-specific regulation of cell cycle gene transcription and activity in human breast cancer cells. Biochem Pharmacol. 2008, 75: 713-724. 10.1016/j.bcp.2007.09.024.PubMed
18.
go back to reference Nguyen HH, Lavrenov SN, Sundar SN, Nguyen DH, Tseng M, Marconett CN, Kung J, Staub RE, Preobrazhenskaya MN, Bjeldanes LF, Firestone GL: 1-Benzyl-indole-3-carbinol is a novel indole-3-carbinol derivative with significantly enhanced potency of anti-proliferative and anti-estrogenic properties in human breast cancer cells. Chem Biol Interact. 2010, 186: 255-266. 10.1016/j.cbi.2010.05.015.PubMedPubMedCentral Nguyen HH, Lavrenov SN, Sundar SN, Nguyen DH, Tseng M, Marconett CN, Kung J, Staub RE, Preobrazhenskaya MN, Bjeldanes LF, Firestone GL: 1-Benzyl-indole-3-carbinol is a novel indole-3-carbinol derivative with significantly enhanced potency of anti-proliferative and anti-estrogenic properties in human breast cancer cells. Chem Biol Interact. 2010, 186: 255-266. 10.1016/j.cbi.2010.05.015.PubMedPubMedCentral
19.
go back to reference Kronbak R, Duus F, Vang O: Effect of 4-methoxyindole-3-carbinol on the proliferation of colon cancer cells in vitro, when treated alone or in combination with indole-3-carbinol. J Agric Food Chem. 2010, 58: 8453-8459. 10.1021/jf101806t.PubMed Kronbak R, Duus F, Vang O: Effect of 4-methoxyindole-3-carbinol on the proliferation of colon cancer cells in vitro, when treated alone or in combination with indole-3-carbinol. J Agric Food Chem. 2010, 58: 8453-8459. 10.1021/jf101806t.PubMed
20.
go back to reference Brandi G, Paiardini M, Cervasi B, Fiorucci C, Filippone P, De Marco C, Zaffaroni N, Magnani M: A new indole-3-carbinol tetrameric derivative inhibits cyclin-dependent kinase 6 expression, and induces G1 cell cycle arrest in both estrogen-dependent and estrogen-independent breast cancer cell lines. Cancer Res. 2003, 63: 4028-4036.PubMed Brandi G, Paiardini M, Cervasi B, Fiorucci C, Filippone P, De Marco C, Zaffaroni N, Magnani M: A new indole-3-carbinol tetrameric derivative inhibits cyclin-dependent kinase 6 expression, and induces G1 cell cycle arrest in both estrogen-dependent and estrogen-independent breast cancer cell lines. Cancer Res. 2003, 63: 4028-4036.PubMed
21.
go back to reference Lucarini S, De Santi M, Antonietti F, Brandi G, Diamantini G, Fraternale A, Paoletti MF, Tontini A, Magnani M, Duranti A: Synthesis and biological evaluation of a γ-cyclodextrin-based formulation of the anticancer agent 5,6,11,12,17,18,23,24-octahydrocyclododeca[1,2-b:4,5-b':7,8-b":10,11-b'"]tetraindole (CTet). Molecules. 2010, 15: 4085-4093. 10.3390/molecules15064085.PubMedPubMedCentral Lucarini S, De Santi M, Antonietti F, Brandi G, Diamantini G, Fraternale A, Paoletti MF, Tontini A, Magnani M, Duranti A: Synthesis and biological evaluation of a γ-cyclodextrin-based formulation of the anticancer agent 5,6,11,12,17,18,23,24-octahydrocyclododeca[1,2-b:4,5-b':7,8-b":10,11-b'"]tetraindole (CTet). Molecules. 2010, 15: 4085-4093. 10.3390/molecules15064085.PubMedPubMedCentral
22.
go back to reference Jackson A, Prasitpan N, Shannon P, Tinker A: Electrophilic substitution in indoles. Part 15. The reaction between methylenedi-indoles and p-nitrobenzenediazonium fluoroborate. J Chem Soc Perkin Trans 1. 1987, 1: 2543-2551. 10.1039/p19870002543. Jackson A, Prasitpan N, Shannon P, Tinker A: Electrophilic substitution in indoles. Part 15. The reaction between methylenedi-indoles and p-nitrobenzenediazonium fluoroborate. J Chem Soc Perkin Trans 1. 1987, 1: 2543-2551. 10.1039/p19870002543.
23.
go back to reference Amatori S, Bagaloni I, Macedi E, Formica M, Giorgi L, Fusi V, Fanelli M: Malten, a new synthetic molecule showing in vitro antiproliferative activity against tumour cells and induction of complex DNA structural alterations. Br J Cancer. 2010, 103: 239-248. 10.1038/sj.bjc.6605745.PubMedPubMedCentral Amatori S, Bagaloni I, Macedi E, Formica M, Giorgi L, Fusi V, Fanelli M: Malten, a new synthetic molecule showing in vitro antiproliferative activity against tumour cells and induction of complex DNA structural alterations. Br J Cancer. 2010, 103: 239-248. 10.1038/sj.bjc.6605745.PubMedPubMedCentral
25.
go back to reference Cheadle C, Vawter MP, Freed WJ, Becker KG: Analysis of microarray data using Z score transformation. J Mol Diagn. 2003, 5: 73-81. 10.1016/S1525-1578(10)60455-2.PubMedPubMedCentral Cheadle C, Vawter MP, Freed WJ, Becker KG: Analysis of microarray data using Z score transformation. J Mol Diagn. 2003, 5: 73-81. 10.1016/S1525-1578(10)60455-2.PubMedPubMedCentral
26.
go back to reference Benjamini Y, Hochberg Y: Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Statist Soc B. 1995, 57: 289-300. Benjamini Y, Hochberg Y: Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Statist Soc B. 1995, 57: 289-300.
28.
go back to reference Manning BD, Cantley LC: AKT/PKB signaling: navigating downstream. Cell. 2007, 129: 1261-1274. 10.1016/j.cell.2007.06.009.PubMedPubMedCentral Manning BD, Cantley LC: AKT/PKB signaling: navigating downstream. Cell. 2007, 129: 1261-1274. 10.1016/j.cell.2007.06.009.PubMedPubMedCentral
29.
go back to reference Seoane J, Le HV, Shen L, Anderson SA, Massagué J: Integration of Smad and forkhead pathways in the control of neuroepithelial and glioblastoma cell proliferation. Cell. 2004, 117: 211-223. 10.1016/S0092-8674(04)00298-3.PubMed Seoane J, Le HV, Shen L, Anderson SA, Massagué J: Integration of Smad and forkhead pathways in the control of neuroepithelial and glioblastoma cell proliferation. Cell. 2004, 117: 211-223. 10.1016/S0092-8674(04)00298-3.PubMed
30.
go back to reference Levi F, Bosetti C, Lucchini F, Negri E, La Vecchia C: Monitoring the decrease in breast cancer mortality in Europe. Eur J Cancer Prev. 2005, 14: 497-502. 10.1097/00008469-200512000-00002.PubMed Levi F, Bosetti C, Lucchini F, Negri E, La Vecchia C: Monitoring the decrease in breast cancer mortality in Europe. Eur J Cancer Prev. 2005, 14: 497-502. 10.1097/00008469-200512000-00002.PubMed
31.
go back to reference Berry DA, Cronin KA, Plevritis SK, Fryback DG, Clarke L, Zelen M, Mandelblatt JS, Yakovlev AY, Habbema JD, Feuer EJ: Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med. 2005, 353: 1784-1792. 10.1056/NEJMoa050518.PubMed Berry DA, Cronin KA, Plevritis SK, Fryback DG, Clarke L, Zelen M, Mandelblatt JS, Yakovlev AY, Habbema JD, Feuer EJ: Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med. 2005, 353: 1784-1792. 10.1056/NEJMoa050518.PubMed
32.
go back to reference Overgaard M, Jensen MB, Overgaard J, Hansen PS, Rose C, Andersson M, Kamby C, Kjaer M, Gadeberg CC, Rasmussen BB, Blichert-Toft M, Mouridsen HT: Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial. Lancet. 1999, 353: 1641-1648. 10.1016/S0140-6736(98)09201-0.PubMed Overgaard M, Jensen MB, Overgaard J, Hansen PS, Rose C, Andersson M, Kamby C, Kjaer M, Gadeberg CC, Rasmussen BB, Blichert-Toft M, Mouridsen HT: Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial. Lancet. 1999, 353: 1641-1648. 10.1016/S0140-6736(98)09201-0.PubMed
33.
go back to reference Early Breast Cancer Trialists' Collaborative Group (EBCTCG): Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005, 365: 1687-1717. 10.1016/S0140-6736(05)66544-0. Early Breast Cancer Trialists' Collaborative Group (EBCTCG): Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005, 365: 1687-1717. 10.1016/S0140-6736(05)66544-0.
34.
go back to reference Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P: Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol. 2007, 18: 581-592. 10.1093/annonc/mdl498.PubMed Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P: Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol. 2007, 18: 581-592. 10.1093/annonc/mdl498.PubMed
35.
go back to reference Jemal A, Siegel R, Xu J, Ward E: Cancer statistics, 2010. CA Cancer J Clin. 2010, 60: 277-300. 10.3322/caac.20073.PubMed Jemal A, Siegel R, Xu J, Ward E: Cancer statistics, 2010. CA Cancer J Clin. 2010, 60: 277-300. 10.3322/caac.20073.PubMed
36.
go back to reference Rahimi M, Huang KL, Tang CK: 3,3'-Diindolylmethane (DIM) inhibits the growth and invasion of drug-resistant human cancer cells expressing EGFR mutants. Cancer Lett. 2010, 295: 59-68. 10.1016/j.canlet.2010.02.014.PubMedPubMedCentral Rahimi M, Huang KL, Tang CK: 3,3'-Diindolylmethane (DIM) inhibits the growth and invasion of drug-resistant human cancer cells expressing EGFR mutants. Cancer Lett. 2010, 295: 59-68. 10.1016/j.canlet.2010.02.014.PubMedPubMedCentral
37.
go back to reference Bergman J, Högberg S, Lindström JO: Macrocyclic condensation products of indole and simple aldehydes. Tetrahedron. 1970, 26: 3347-3352. 10.1016/S0040-4020(01)92912-6. Bergman J, Högberg S, Lindström JO: Macrocyclic condensation products of indole and simple aldehydes. Tetrahedron. 1970, 26: 3347-3352. 10.1016/S0040-4020(01)92912-6.
38.
go back to reference Staub RE, Bjeldanes LF: Convenient synthesis of 5,6,11,12,17,18- hexahydrocyclononal[1,2-b:4,5-b':7,8-b"]triindole, a novel phytoestrogen. J Org Chem. 2003, 68: 167-169. 10.1021/jo020415y.PubMed Staub RE, Bjeldanes LF: Convenient synthesis of 5,6,11,12,17,18- hexahydrocyclononal[1,2-b:4,5-b':7,8-b"]triindole, a novel phytoestrogen. J Org Chem. 2003, 68: 167-169. 10.1021/jo020415y.PubMed
39.
go back to reference Glick D, Barth S, Macleod KF: Autophagy: cellular and molecular mechanisms. J Pathol. 2010, 221: 3-12. 10.1002/path.2697.PubMedPubMedCentral Glick D, Barth S, Macleod KF: Autophagy: cellular and molecular mechanisms. J Pathol. 2010, 221: 3-12. 10.1002/path.2697.PubMedPubMedCentral
40.
go back to reference White E, DiPaola RS: The double-edged sword of autophagy modulation in cancer. Clin Cancer Res. 2009, 15: 5308-5316. 10.1158/1078-0432.CCR-07-5023.PubMedPubMedCentral White E, DiPaola RS: The double-edged sword of autophagy modulation in cancer. Clin Cancer Res. 2009, 15: 5308-5316. 10.1158/1078-0432.CCR-07-5023.PubMedPubMedCentral
41.
go back to reference Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D: p21 is a universal inhibitor of cyclin kinases. Nature. 1993, 366: 701-704. 10.1038/366701a0.PubMed Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D: p21 is a universal inhibitor of cyclin kinases. Nature. 1993, 366: 701-704. 10.1038/366701a0.PubMed
42.
go back to reference Wendt J, Radetzki S, von Haefen C, Hemmati PG, Guner D, Schulze-Osthoff K, Dorken B, Daniel PT: Induction of p21CIP/WAF-1 and G2 arrest by ionizing irradiation impedes caspase-3-mediated apoptosis in human carcinoma cells. Oncogene. 2006, 25: 972-980. 10.1038/sj.onc.1209031.PubMed Wendt J, Radetzki S, von Haefen C, Hemmati PG, Guner D, Schulze-Osthoff K, Dorken B, Daniel PT: Induction of p21CIP/WAF-1 and G2 arrest by ionizing irradiation impedes caspase-3-mediated apoptosis in human carcinoma cells. Oncogene. 2006, 25: 972-980. 10.1038/sj.onc.1209031.PubMed
43.
go back to reference Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ: The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell. 1993, 75: 805-816. 10.1016/0092-8674(93)90499-G.PubMed Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ: The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell. 1993, 75: 805-816. 10.1016/0092-8674(93)90499-G.PubMed
44.
go back to reference Harper JW, Elledge SJ, Keyomarsi K, Dynlacht B, Tsai LH, Zhang P, Dobrowolski S, Bai C, Connell-Crowley L, Swindell E, Fox MP, Wei N: Inhibition of cyclin-dependent kinases by p21. Mol Biol Cell. 1995, 6: 387-400.PubMedPubMedCentral Harper JW, Elledge SJ, Keyomarsi K, Dynlacht B, Tsai LH, Zhang P, Dobrowolski S, Bai C, Connell-Crowley L, Swindell E, Fox MP, Wei N: Inhibition of cyclin-dependent kinases by p21. Mol Biol Cell. 1995, 6: 387-400.PubMedPubMedCentral
45.
go back to reference Jin S, Antinore MJ, Lung FD, Dong X, Zhao H, Fan F, Colchagie AB, Blanck P, Roller PP, Fornace AJ, Zhan Q: The GADD45 inhibition of Cdc2 kinase correlates with GADD45-mediated growth suppression. J Biol Chem. 2000, 275: 16602-16608. 10.1074/jbc.M000284200.PubMed Jin S, Antinore MJ, Lung FD, Dong X, Zhao H, Fan F, Colchagie AB, Blanck P, Roller PP, Fornace AJ, Zhan Q: The GADD45 inhibition of Cdc2 kinase correlates with GADD45-mediated growth suppression. J Biol Chem. 2000, 275: 16602-16608. 10.1074/jbc.M000284200.PubMed
46.
go back to reference Gao H, Jin S, Song Y, Fu M, Wang M, Liu Z, Wu M, Zhan Q: B23 regulates GADD45a nuclear translocation and contributes to GADD45a-induced cell cycle G2-M arrest. J Biol Chem. 2005, 280: 10988-10996. 10.1074/jbc.M412720200.PubMed Gao H, Jin S, Song Y, Fu M, Wang M, Liu Z, Wu M, Zhan Q: B23 regulates GADD45a nuclear translocation and contributes to GADD45a-induced cell cycle G2-M arrest. J Biol Chem. 2005, 280: 10988-10996. 10.1074/jbc.M412720200.PubMed
47.
go back to reference Chai Y, Lee HJ, Shaik AA, Nkhata K, Xing C, Zhang J, Jeong SJ, Kim SH, Lu J: Penta-O-galloyl-β-D-glucose induces G1 arrest and DNA replicative S-phase arrest independently of P21 cyclin-dependent kinase inhibitor 1A, P27 cyclin-dependent kinase inhibitor 1B and P53 in human breast cancer cells and is orally active against triple-negative xenograft growth. Breast Cancer Res. 2010, 12: R67-10.1186/bcr2634.PubMedPubMedCentral Chai Y, Lee HJ, Shaik AA, Nkhata K, Xing C, Zhang J, Jeong SJ, Kim SH, Lu J: Penta-O-galloyl-β-D-glucose induces G1 arrest and DNA replicative S-phase arrest independently of P21 cyclin-dependent kinase inhibitor 1A, P27 cyclin-dependent kinase inhibitor 1B and P53 in human breast cancer cells and is orally active against triple-negative xenograft growth. Breast Cancer Res. 2010, 12: R67-10.1186/bcr2634.PubMedPubMedCentral
48.
go back to reference Li Y, Upadhyay S, Bhuiyan M, Sarkar FH: Induction of apoptosis in breast cancer cells MDA-MB-231 by genistein. Oncogene. 1999, 18: 3166-3172. 10.1038/sj.onc.1202650.PubMed Li Y, Upadhyay S, Bhuiyan M, Sarkar FH: Induction of apoptosis in breast cancer cells MDA-MB-231 by genistein. Oncogene. 1999, 18: 3166-3172. 10.1038/sj.onc.1202650.PubMed
49.
go back to reference Gotea V, Ovcharenko I: DiRE: identifying distant regulatory elements of co-expressed genes. Nucleic Acids Res. 2008, 36: W133-139. 10.1093/nar/gkn300.PubMedPubMedCentral Gotea V, Ovcharenko I: DiRE: identifying distant regulatory elements of co-expressed genes. Nucleic Acids Res. 2008, 36: W133-139. 10.1093/nar/gkn300.PubMedPubMedCentral
51.
go back to reference Zhu QS, Ren W, Korchin B, Lahat G, Dicker A, Lu Y, Mills G, Pollock RE, Lev D: Soft tissue sarcoma cells are highly sensitive to AKT blockade: a role for p53-independent up-regulation of GADD45α. Cancer Res. 2008, 68: 2895-2903. 10.1158/0008-5472.CAN-07-6268.PubMedPubMedCentral Zhu QS, Ren W, Korchin B, Lahat G, Dicker A, Lu Y, Mills G, Pollock RE, Lev D: Soft tissue sarcoma cells are highly sensitive to AKT blockade: a role for p53-independent up-regulation of GADD45α. Cancer Res. 2008, 68: 2895-2903. 10.1158/0008-5472.CAN-07-6268.PubMedPubMedCentral
Metadata
Title
The indole-3-carbinol cyclic tetrameric derivative CTet inhibits cell proliferation via overexpression of p21/CDKN1A in both estrogen receptor-positive and triple-negative breast cancer cell lines
Authors
Mauro De Santi
Luca Galluzzi
Simone Lucarini
Maria Filomena Paoletti
Alessandra Fraternale
Andrea Duranti
Cinzia De Marco
Mirco Fanelli
Nadia Zaffaroni
Giorgio Brandi
Mauro Magnani
Publication date
01-04-2011
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 2/2011
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr2855

Other articles of this Issue 2/2011

Breast Cancer Research 2/2011 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine